Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
HETLIOZ® is a melatonin receptor agonist. HETLIOZ® received U.S. Food and Drug Administration approval in January 2014 for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ® received European Commision approval in July 2015 for the treatment of Non-24 in totally blind adults in the European Union.
Full HETLIOZ® Prescribing Information can be found at: www.hetlioz.com.
Fanapt® is an atypical antipsychotic approved for the treatment of schizophrenia in adults. Fanapt® is a serotonin (5-HT2) receptor and dopamine receptor antagonist.
Fanapt® received U.S. Food and Drug Administration approval in May 2009. In addition, Vanda currently has Fanapt® distribution partnerships in Israel and Mexico. In 2012, Fanapt® was approved for marketing in Israel and Argentina.
For U.S. full prescribing information, including box warnings and safety information, please visit www.fanapt.com.